Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

@article{Chen2005ClinicalPO,
  title={Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease},
  author={J. Chen and D. Swope},
  journal={The Journal of Clinical Pharmacology},
  year={2005},
  volume={45}
}
  • J. Chen, D. Swope
  • Published 2005
  • Medicine
  • The Journal of Clinical Pharmacology
  • Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO‐B with a potency 5 to 10 times greater than selegiline. Unlike the prototype… CONTINUE READING
    117 Citations
    Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    • J. Chen, A. Ly
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2006
    • 49
    Rasagiline in treatment of Parkinson’s disease
    • 18
    • PDF
    Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
    • 132
    Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
    • 7
    • Highly Influenced
    Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease
    • T. Müller
    • Medicine
    • Expert opinion on drug metabolism & toxicology
    • 2014
    • 10
    Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease
    • 9
    • Highly Influenced
    • PDF
    Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease
    • 148
    • PDF
    Safety of rasagiline for the treatment of Parkinson's disease
    • 25

    References

    SHOWING 1-10 OF 111 REFERENCES
    The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing
    • 106
    Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa
    • 152
    • Highly Influential
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline
    • 40
    Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
    • 285
    • Highly Influential
    Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.
    • 149
    Neuroprotective actions of selegiline
    • 112
    Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
    • 143
    Effect of lazabemide on the progression of disability in early Parkinson's disease
    • 110
    Clinical Pharmacokinetics and Pharmacodynamics of Selegiline
    • 96